Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 study

Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 study

We evaluated the feasibility of ruxolitinib therapy followed by a reduced-intensity conditioning (RIC) regimen for patients with myelofibrosis (MF) undergoing transplantation in a 2-stage Simon phase II trial. The aims were to decrease the incidence of graft failure (GF) and nonrelapse mortality (NR...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính:	Gupta, V, Kosiorek, H, Mead, A, Klisovic, R, Galvin, J, Berenzon, D, Yacoub, A, Viswabandya, A, Mesa, R, Goldberg, J, Price, L, Salama, M, Weinberg, R, Rampal, R, Farnoud, N, Dueck, A, Mascarenhas, J, Hoffman, R
Định dạng:	Journal article
Ngôn ngữ:	English
Được phát hành:	Elsevier 2018

Những quyển sách tương tự

Practical management of patients with myelofibrosis receiving ruxolitinib.
Bằng: Harrison, C, et al.
Được phát hành: (2013)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential
Bằng: Ostojic A, et al.
Được phát hành: (2012-03-01)

P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
Bằng: V. Gupta, et al.
Được phát hành: (2022-06-01)

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Bằng: Srdan Verstovsek, et al.
Được phát hành: (2023-07-01)

Ruxolitinib as an emerging treatment in myelofibrosis
Bằng: Emanuel RM, et al.
Được phát hành: (2013-03-01)

Hemostasis in patients with primary myelofibrosis treated with ruxolitinib
Bằng: O. G. Golovina, et al.
Được phát hành: (2024-11-01)

P1057: REAL-WORLD UTILIZATION OF FEDRATINIB FOR MYELOFIBROSIS FOLLOWING RUXOLITINIB FAILURE
Bằng: C. Harrison, et al.
Được phát hành: (2022-06-01)

S198: BET INHIBITOR PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS — JAK INHIBITOR-NAÏVE OR WITH SUBOPTIMAL RESPONSE TO RUXOLITINIB — PRELIMINARY DATA FROM THE MANIFEST STUDY
Bằng: J. Mascarenhas, et al.
Được phát hành: (2022-06-01)

The UK Myeloproliferative Neoplasm Registry for Myelofibrosis (UK-MPN-MF registry)
Bằng: Butt, N, et al.
Được phát hành: (2019)

Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence
Bằng: Harrison, C, et al.
Được phát hành: (2016)

JAK inhibitors and myelofibrosis, Einstein and ruxolitinib
Bằng: Claire Harrison
Được phát hành: (2015-04-01)

P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA
Bằng: C. Harrison, et al.
Được phát hành: (2022-06-01)

Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications
Bằng: David M. Ross, et al.
Được phát hành: (2021-01-01)

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis
Bằng: Naval Daver, et al.
Được phát hành: (2015-08-01)

P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYELOFIBROSIS PATIENTS
Bằng: C. Harrison, et al.
Được phát hành: (2022-06-01)

P1010: RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME
Bằng: F. Palandri, et al.
Được phát hành: (2022-06-01)

Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib
Bằng: Maheen Z. Abidi, et al.
Được phát hành: (2016-01-01)

Unusual cause of dyspnea in patient with Myelofibrosis: The Ruxolitinib lung
Bằng: Antoine El Kik, et al.
Được phát hành: (2024-01-01)

Marked Hyperbilirubinemia Associated with Primary Myelofibrosis Responsive to Ruxolitinib
Bằng: Sunny Sandhu, et al.
Được phát hành: (2022-01-01)

The Gordian knot: ruxolitinib or transplants for high-risk myelofibrosis
Bằng: Robert Peter Gale, et al.
Được phát hành: (2024-07-01)

P991: IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB
Bằng: P. Harrington, et al.
Được phát hành: (2022-06-01)

Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms
Bằng: Eylem Eliaçık, et al.
Được phát hành: (2015-05-01)

The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib
Bằng: Douglas Tremblay, et al.
Được phát hành: (2019-01-01)

RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort
Bằng: O'Sullivan, JM, et al.
Được phát hành: (2023)

A phase I trial of pevonedistat in combination with ruxolitinib for the treatment of myelofibrosis
Bằng: Tim Kong, et al.
Được phát hành: (2024-03-01)

Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation
Bằng: Leona Dold, et al.
Được phát hành: (2021-09-01)

Decision analysis for transplant candidates with primary myelofibrosis in the ruxolitinib era
Bằng: Yosuke Okada, et al.
Được phát hành: (2024-06-01)

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
Bằng: Bewersdorf JP, et al.
Được phát hành: (2019-12-01)

P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA
Bằng: Z. Xu, et al.
Được phát hành: (2022-06-01)

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival
Bằng: Maymona G. Abdelmagid, et al.
Được phát hành: (2023-02-01)

P1044: REAL-WORLD RUXOLITINIB TREATMENT PATTERN IN MYELOFIBROSIS PATIENTS WITH THROMBOCYTOPENIA
Bằng: J. Mei, et al.
Được phát hành: (2022-06-01)

TGF-β signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche
Bằng: Juo-Chin Yao, et al.
Được phát hành: (2022-06-01)

Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis
Bằng: Bing Li, et al.
Được phát hành: (2017-05-01)

Disseminated Histoplasmosis in a Patient with Myelofibrosis on Ruxolitinib: A Case Report and Review of the Literature on Ruxolitinib-Associated Invasive Fungal Infections
Bằng: Chia-Yu Chiu, et al.
Được phát hành: (2024-03-01)

High Incidence of Herpes Zoster in Patients Using Ruxolitinib for Myeloproliferative Neoplasms: Need for Prophylaxis
Bằng: Elsemieke te Linde, et al.
Được phát hành: (2022-11-01)

Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study
Bằng: Moshe Talpaz, et al.
Được phát hành: (2018-08-01)

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis
Bằng: Claire Harrison, et al.
Được phát hành: (2022-08-01)

Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib
Bằng: Vera Stoeva, et al.
Được phát hành: (2023-07-01)

Ruxolitinib for CALR-positive Myelofibrosis: A Case Report and Literature Review
Bằng: GUO Huimei, et al.
Được phát hành: (2018-08-01)

P1018: TREND OF CIRCULATING CD34+ CELLS IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB
Bằng: D. Cattaneo, et al.
Được phát hành: (2022-06-01)